1
|
Mayr CH, Sengupta A, Asgharpour S, Ansari M, Pestoni JC, Ogar P, Angelidis I, Liontos A, Rodriguez-Castillo JA, Lang NJ, Strunz M, Porras-Gonzalez D, Gerckens M, De Sadeleer LJ, Oehrle B, Viteri-Alvarez V, Fernandez IE, Tallquist M, Irmler M, Beckers J, Eickelberg O, Stoleriu GM, Behr J, Kneidinger N, Wuyts WA, Wasnick RM, Yildirim AÖ, Ahlbrecht K, Morty RE, Samakovlis C, Theis FJ, Burgstaller G, Schiller HB. Sfrp1 inhibits lung fibroblast invasion during transition to injury-induced myofibroblasts. Eur Respir J 2024; 63:2301326. [PMID: 38212077 PMCID: PMC10850614 DOI: 10.1183/13993003.01326-2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Accepted: 11/13/2023] [Indexed: 01/13/2024]
Abstract
BACKGROUND Fibroblast-to-myofibroblast conversion is a major driver of tissue remodelling in organ fibrosis. Distinct lineages of fibroblasts support homeostatic tissue niche functions, yet their specific activation states and phenotypic trajectories during injury and repair have remained unclear. METHODS We combined spatial transcriptomics, multiplexed immunostainings, longitudinal single-cell RNA-sequencing and genetic lineage tracing to study fibroblast fates during mouse lung regeneration. Our findings were validated in idiopathic pulmonary fibrosis patient tissues in situ as well as in cell differentiation and invasion assays using patient lung fibroblasts. Cell differentiation and invasion assays established a function of SFRP1 in regulating human lung fibroblast invasion in response to transforming growth factor (TGF)β1. MEASUREMENTS AND MAIN RESULTS We discovered a transitional fibroblast state characterised by high Sfrp1 expression, derived from both Tcf21-Cre lineage positive and negative cells. Sfrp1 + cells appeared early after injury in peribronchiolar, adventitial and alveolar locations and preceded the emergence of myofibroblasts. We identified lineage-specific paracrine signals and inferred converging transcriptional trajectories towards Sfrp1 + transitional fibroblasts and Cthrc1 + myofibroblasts. TGFβ1 downregulated SFRP1 in noninvasive transitional cells and induced their switch to an invasive CTHRC1+ myofibroblast identity. Finally, using loss-of-function studies we showed that SFRP1 modulates TGFβ1-induced fibroblast invasion and RHOA pathway activity. CONCLUSIONS Our study reveals the convergence of spatially and transcriptionally distinct fibroblast lineages into transcriptionally uniform myofibroblasts and identifies SFRP1 as a modulator of TGFβ1-driven fibroblast phenotypes in fibrogenesis. These findings are relevant in the context of therapeutic interventions that aim at limiting or reversing fibroblast foci formation.
Collapse
Affiliation(s)
- Christoph H Mayr
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
- C.H. Mayr and A. Sengupta contributed equally to this work
| | - Arunima Sengupta
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
- C.H. Mayr and A. Sengupta contributed equally to this work
| | - Sara Asgharpour
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Meshal Ansari
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
- Institute of Computational Biology, Helmholtz Munich, Munich, Germany
| | - Jeanine C Pestoni
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Paulina Ogar
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Ilias Angelidis
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Andreas Liontos
- Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
- SciLifeLab, Stockholm, Sweden
| | | | - Niklas J Lang
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Maximilian Strunz
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Diana Porras-Gonzalez
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Michael Gerckens
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
- Department of Internal Medicine V, Ludwig-Maximilians University (LMU) Munich, Member of the German Center for Lung Research (DZL), CPC-M bioArchive, Munich, Germany
| | - Laurens J De Sadeleer
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
- Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department CHROMETA, KU Leuven, Leuven, Belgium
| | - Bettina Oehrle
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Valeria Viteri-Alvarez
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Isis E Fernandez
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Michelle Tallquist
- Center for Cardiovascular Research, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
| | - Martin Irmler
- Institute of Experimental Genetics, Helmholtz Zentrum München, Neuherberg, Germany
| | - Johannes Beckers
- Institute of Experimental Genetics, Helmholtz Zentrum München, Neuherberg, Germany
- German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany
- Chair of Experimental Genetics, Technical University of Munich, Freising, Germany
| | - Oliver Eickelberg
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
| | - Gabriel Mircea Stoleriu
- Department of Internal Medicine V, Ludwig-Maximilians University (LMU) Munich, Member of the German Center for Lung Research (DZL), CPC-M bioArchive, Munich, Germany
| | - Jürgen Behr
- Department of Internal Medicine V, Ludwig-Maximilians University (LMU) Munich, Member of the German Center for Lung Research (DZL), CPC-M bioArchive, Munich, Germany
| | - Nikolaus Kneidinger
- Department of Internal Medicine V, Ludwig-Maximilians University (LMU) Munich, Member of the German Center for Lung Research (DZL), CPC-M bioArchive, Munich, Germany
| | - Wim A Wuyts
- Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department CHROMETA, KU Leuven, Leuven, Belgium
| | - Roxana Maria Wasnick
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Ali Önder Yildirim
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
- Institute of Experimental Pneumology, LMU University Hospital, Ludwig-Maximilians University, Munich, Germany
| | - Katrin Ahlbrecht
- Max Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Bad Nauheim, Germany
| | - Rory E Morty
- Department of Translational Pulmonology, University Hospital Heidelberg, and Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
| | - Christos Samakovlis
- Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
- SciLifeLab, Stockholm, Sweden
| | - Fabian J Theis
- Institute of Computational Biology, Helmholtz Munich, Munich, Germany
- Department of Mathematics, Technische Universität München, Munich, Germany
| | - Gerald Burgstaller
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
- G. Burgstaller and H.B. Schiller contributed equally to this article as lead authors and supervised the work
| | - Herbert B Schiller
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
- Institute of Experimental Pneumology, LMU University Hospital, Ludwig-Maximilians University, Munich, Germany
- G. Burgstaller and H.B. Schiller contributed equally to this article as lead authors and supervised the work
| |
Collapse
|
2
|
Rapti I, Asimakopoulos A, Liontos A, Kosmidou M, Christaki E, Biros D, Milionis O, Tsourlos S, Ntotsikas E, Ntzani E, Evangelou E, Gartzonika K, Georgiou I, Tzoulaki I, Tsilidis K, Milionis H. Association of patient characteristics with clinical outcomes in a cohort of hospitalised patients with SARS-CoV-2 infection in a Greek referral centre for COVID-19 - Corrigendum. Epidemiol Infect 2023; 151:e91. [PMID: 37288502 DOI: 10.1017/s0950268823000857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023] Open
Affiliation(s)
- I Rapti
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| | - A Asimakopoulos
- Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece
| | - A Liontos
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| | - M Kosmidou
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| | - E Christaki
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| | - D Biros
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| | - O Milionis
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| | - S Tsourlos
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| | - E Ntotsikas
- Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece
| | - E Ntzani
- Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece
- Center for Evidence-Based Medicine, Department of Health Services, Policy and Practice, School of Public Health, Brown University, Providence, RI, USA
| | - E Evangelou
- Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - K Gartzonika
- Microbiology Department, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina45110, Greece
| | - I Georgiou
- Genetics and IVF Unit, Department of Obstetrics and Gynaecology, Medical School, University of Ioannina, Ioannina45110, Greece
| | - I Tzoulaki
- Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - K Tsilidis
- Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - H Milionis
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| |
Collapse
|
3
|
Sountoulidis A, Marco Salas S, Braun E, Avenel C, Bergenstråhle J, Theelke J, Vicari M, Czarnewski P, Liontos A, Abalo X, Andrusivová Ž, Mirzazadeh R, Asp M, Li X, Hu L, Sariyar S, Martinez Casals A, Ayoglu B, Firsova A, Michaëlsson J, Lundberg E, Wählby C, Sundström E, Linnarsson S, Lundeberg J, Nilsson M, Samakovlis C. A topographic atlas defines developmental origins of cell heterogeneity in the human embryonic lung. Nat Cell Biol 2023; 25:351-365. [PMID: 36646791 PMCID: PMC9928586 DOI: 10.1038/s41556-022-01064-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Accepted: 11/23/2022] [Indexed: 01/18/2023]
Abstract
The lung contains numerous specialized cell types with distinct roles in tissue function and integrity. To clarify the origins and mechanisms generating cell heterogeneity, we created a comprehensive topographic atlas of early human lung development. Here we report 83 cell states and several spatially resolved developmental trajectories and predict cell interactions within defined tissue niches. We integrated single-cell RNA sequencing and spatially resolved transcriptomics into a web-based, open platform for interactive exploration. We show distinct gene expression programmes, accompanying sequential events of cell differentiation and maturation of the secretory and neuroendocrine cell types in proximal epithelium. We define the origin of airway fibroblasts associated with airway smooth muscle in bronchovascular bundles and describe a trajectory of Schwann cell progenitors to intrinsic parasympathetic neurons controlling bronchoconstriction. Our atlas provides a rich resource for further research and a reference for defining deviations from homeostatic and repair mechanisms leading to pulmonary diseases.
Collapse
Affiliation(s)
- Alexandros Sountoulidis
- grid.452834.c0000 0004 5911 2402Science for Life Laboratory, Solna, Sweden ,grid.10548.380000 0004 1936 9377Department of Molecular Biosciences, Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
| | - Sergio Marco Salas
- grid.452834.c0000 0004 5911 2402Science for Life Laboratory, Solna, Sweden ,grid.10548.380000 0004 1936 9377Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden
| | - Emelie Braun
- grid.4714.60000 0004 1937 0626Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
| | - Christophe Avenel
- grid.8993.b0000 0004 1936 9457Department of Information Technology, Uppsala University, Uppsala, Sweden ,grid.452834.c0000 0004 5911 2402BioImage Informatics Facility, Science for Life Laboratory, SciLifeLab, Sweden
| | - Joseph Bergenstråhle
- grid.5037.10000000121581746Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Jonas Theelke
- grid.452834.c0000 0004 5911 2402Science for Life Laboratory, Solna, Sweden ,grid.10548.380000 0004 1936 9377Department of Molecular Biosciences, Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
| | - Marco Vicari
- grid.5037.10000000121581746Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Paulo Czarnewski
- grid.5037.10000000121581746Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Andreas Liontos
- grid.452834.c0000 0004 5911 2402Science for Life Laboratory, Solna, Sweden ,grid.10548.380000 0004 1936 9377Department of Molecular Biosciences, Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
| | - Xesus Abalo
- grid.5037.10000000121581746Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Žaneta Andrusivová
- grid.5037.10000000121581746Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Reza Mirzazadeh
- grid.5037.10000000121581746Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Michaela Asp
- grid.5037.10000000121581746Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Xiaofei Li
- grid.4714.60000 0004 1937 0626Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
| | - Lijuan Hu
- grid.4714.60000 0004 1937 0626Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
| | - Sanem Sariyar
- grid.5037.10000000121581746Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden
| | - Anna Martinez Casals
- grid.5037.10000000121581746Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden
| | - Burcu Ayoglu
- grid.5037.10000000121581746Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden
| | - Alexandra Firsova
- grid.452834.c0000 0004 5911 2402Science for Life Laboratory, Solna, Sweden ,grid.10548.380000 0004 1936 9377Department of Molecular Biosciences, Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
| | - Jakob Michaëlsson
- grid.4714.60000 0004 1937 0626Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
| | - Emma Lundberg
- grid.5037.10000000121581746Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden
| | - Carolina Wählby
- grid.8993.b0000 0004 1936 9457Department of Information Technology, Uppsala University, Uppsala, Sweden ,grid.452834.c0000 0004 5911 2402BioImage Informatics Facility, Science for Life Laboratory, SciLifeLab, Sweden
| | - Erik Sundström
- grid.4714.60000 0004 1937 0626Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
| | - Sten Linnarsson
- grid.4714.60000 0004 1937 0626Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
| | - Joakim Lundeberg
- grid.5037.10000000121581746Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Mats Nilsson
- Science for Life Laboratory, Solna, Sweden. .,Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden.
| | - Christos Samakovlis
- Science for Life Laboratory, Solna, Sweden. .,Department of Molecular Biosciences, Wenner-Gren Institute, Stockholm University, Stockholm, Sweden. .,Molecular Pneumology, Cardiopulmonary Institute, Justus Liebig University, Giessen, Germany.
| |
Collapse
|
4
|
Liontos A, Biros D, Papathanasiou A, Papagiannopoulos C, Klouras E, Veliani C, Kolios NG, Pappa C, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Comparative effect of 3 different fix-combination antihypertensive treatments in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
The effect of various antihypertensive drugs on the glucose homeostasis has been discussed extensively. Dual combination treatment is advised with current guidelines. We present comparative data of the effect of delapril/manidipine versus valsartan/amlodipine versus telmisartan/amlodipine combination treatments, in fasting glucose, fasting insulin, OGTT and HbA1c levels, before and after the 3-month treatment, in hypertensive prediabetic patients.
Methods
Data were collected from 154 patients from the outpatient clinic for patients with lipid disorders, hypertension and diabetes of our hospital, during the period 2014–2018. A number of 53 persons was randomized in the delapril/manidipine group 30/10 mg per day while 51 persons had been randomized in the group of telmisartan/amlodipine 80/5mg per day and 54 patients in the valsartan/amlodipine 160/5 mg per day. All patients successfully completed the study. Baseline characteristics are presented in Table 1A.
Results
The resulting alternations in glucose, insulin, OGTT and HbA1c levels, before and after the 3-month treatment are presented on Table 1B for the 3 groups of treatment.
Conclusions
In the comparison between the groups, a statistically significant difference was found in the change in INS values from the beginning of treatment until 3 months, for the TEL/AMLO treatment group, where a statistically significant difference from the DEL/MANI treatment group (p-value<0.01) and a strong statistically significant difference from the VAL/AMLO treatment group (p-value<0.001) were noted. The TEL/AMLO group had the only decrease in insulin levels compared to the other treatment groups where an increase was observed, after the treatment. The change in OGTT levels showed a statistically significant difference (p-value<0.05) between the DEL/MANI treatment group (a decrease of 6.63%) compared to the TEL/AMLO treatment group (an increase of 1.53%) after 3 months of treatment.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A Liontos
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | - D Biros
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | - A Papathanasiou
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | | | - E Klouras
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | - C Veliani
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | - N G Kolios
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | - C Pappa
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | | | - M Elisaf
- University hospital of Ioannina, 2nd Division of Internal Medicine , Ioannina , Greece
| | - H Milionis
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | - G Liamis
- University hospital of Ioannina, 2nd Division of Internal Medicine , Ioannina , Greece
| |
Collapse
|
5
|
Liontos A, Filippas-Ntekouan S, Biros D, Kolios NG, Papagiannopoulos C, Veliani C, Papathanasiou A, Samanidou V, Tsourlos S, Athanasiou L, Pappa C, Pargana E, Nasiou M, Zarachi A, Vagias I, Tsiakas I, Christaki E, Elisaf M, Liberopoulos E, Milionis H, Liamis G. Comparative effect of valsartan-amlodipine treatment versus telmisartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Liontos A, Biros D, Papathanasiou A, Papagiannopoulos C, Klouras E, Tsourlos S, Athanasiou L, Filippas-Ntekouan S, Zarachi A, Kolios NG, Pappa C, Samanidou V, Christaki E, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Comparative effect of valsartan-amlodipine treatment versus telmisartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
7
|
Liontos A, Biros D, Papathanasiou A, Papagiannopoulos C, Klouras E, Athanasiou L, Tsourlos S, Filippas-Ntekouan S, Samanidou V, Kolios NG, Veliani C, Pappa C, Zarachi A, Christaki E, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Comparative effect of delapril-manidipine treatment versus telmisartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
8
|
Liontos A, Filippas-Ntekouan S, Biros D, Kolios NG, Veliani C, Papagiannopoulos C, Samanidou V, Papathanasiou A, Tsourlos S, Athanasiou L, Pappa C, Pargana E, Nasiou M, Zarachi A, Tsiakas I, Christaki E, Elisaf M, Liberopoulos E, Milionis H, Liamis G. Comparative effect of delapril-manidipine treatment versus telmisartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
9
|
Liontos A, Papathanasiou A, Biros D, Papagiannopoulos C, Tsourlos S, Athanasiou L, Zarachi A, Kolios NG, Pargana E, Nasiou M, Christaki E, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with telmisartan/amlodipine in prediabetic patients. Eur J Prev Cardiol 2022. [DOI: 10.1093/eurjpc/zwac056.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction-Purpose
The combination of telmisartan with amlodipine is a commonly administered combination of an agonist ATII (angiotensin receptor II) and CCB (calcium channel blocker) for the management of hypertension. The purpose of this study is to evaluate the effect of the fixed of combination telmisartan/amlodipine 80/5mg per day on the levels of serum lipids, as well as the levels of serum apolipoproteins and the TRG/ApoA-1, TRG/HDL-C ratios, in patients with stage 2 hypertension (systolic blood pressure (SBP) 160-180 mmHg and/or diastolic blood pressure (DBP) 100-110 mmHg) and with prediabetes (IFG/IGT), before and after the 3-month treatment.
Methods
Data from 51 patients who had visited our outpatient clinic for lipid metabolism disorders during the period 2014-2018 and had been randomized in the telmisartan/amlodipine group 80/5mg per day. The patients (35 male/16 female) had BMI: 29.32 [27.37-31.65]. The levels serum lipids and of apolipoproteins B, A1, Lp(a) and E were measured before the beginning of the treatment and 3-months after its administration.
Results
The resulting variations of SBP and DBP levels before and after the 3-month treatment, as well as the variations of serum lipid, apolipoprotein levels and TRG/ApoA-1, TRG/HDL-C ratios are presented on Table 1.
Conclusion
The 3-month telmisartan/amlodipine therapy seems to improved, statistically significant both SBP and DBP levels (decreased by -13.58 % and -13 % respectively, p<0.001, for both values). Serum lipid levels didn’t show any significant variation before and after treatment. Statistically significant changes were not present in apolipoprotein levels, also. Finally, there were no statistically significant variations in either TRG/ApoA-1 or TRG/HDL-C ratios.
Collapse
Affiliation(s)
- A Liontos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Papathanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - D Biros
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | | | - S Tsourlos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - L Athanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Zarachi
- University Hospital of Ioannina, ENT departement, Ioannina, Greece
| | - NG Kolios
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Pargana
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - M Nasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Christaki
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Liberopoulos
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - M Elisaf
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - H Milionis
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - G Liamis
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| |
Collapse
|
10
|
Liontos A, Papathanasiou A, Biros D, Papagiannopoulos C, Tsourlos S, Athanasiou L, Kolios NG, Pappa C, Veliani C, Zarachi A, Christaki E, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with delapril/manidipine in prediabetic hypertensive patients. Eur J Prev Cardiol 2022. [DOI: 10.1093/eurjpc/zwac056.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Purpose
The administration of the 30mg hydrochloric delapril and 10mg hydrochloric manidipine formulation is indicated for patients with idiopathic hypertension whose arterial pressure cannot be sufficiently managed with monotherapy. The purpose of this study is to investigate the effect of the premade combination delapril/manidipine 30/10mg per day on the variation of HOMA-IR, HOMA-B and QUICKI values, in patients with stage 2 hypertension (systolic blood pressure (SBP) 160-180 mmHg and/or diastolic blood pressure (DBP) 100-110 mmHg) and with prediabetes (IFG/IGT) before and after the 3-month treatment with the fixed combination dual-therapy.
Methods
53 patients (30 male/23 female, from whom 12 smokers and 7 alcohol users) who visited our outpatient clinic for lipid metabolism disorders and fulfilled the study’s criteria joined the study’s sample. They were randomized in the delapril/manidipine group. The patients’ BMI was 28.73 [27.73-30.3] and the SBP and DBP values were: 156 [151-161] and 100 [88-101] mmHg respectively.
Results
The resulting variations of SBP and DBP levels, as well as the variations of glucose and insulin levels and HOMA-IR, HOMA-B and QUICKI are presented on Table 1.
Results
From the sampled patients it seems that the 3-month treatment with delapril/manidipine improved statistically significantly the levels of both SBP and DBP (reduction by -11.54% and -12% respectively, p<0.001 for both values). Glucose levels witnessed a 1.55% decrease with statistical significance while a notable increase in insulin by 4.65% was also observed after the 3-month treatment, albeit without any statistical significance. Concerning HOMA-IR and QUICKI, there were no significant variance, while HOMA-B values showed a statistically significant increase (7%, p=0.006)
Collapse
Affiliation(s)
- A Liontos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Papathanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - D Biros
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | | | - S Tsourlos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - L Athanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - NG Kolios
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - C Pappa
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - C Veliani
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Zarachi
- University Hospital of Ioannina, ENT departement, Ioannina, Greece
| | - E Christaki
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Liberopoulos
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - M Elisaf
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - H Milionis
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - G Liamis
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| |
Collapse
|
11
|
Liontos A, Papathanasiou A, Biros D, Papagiannopoulos C, Tsourlos S, Athanasiou L, Veliani C, Kolios NG, Pappa C, Zarachi A, Christaki E, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with telmisartan/amlodipine in prediabetic hypertensive patients. Eur J Prev Cardiol 2022. [DOI: 10.1093/eurjpc/zwac056.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction-Purpose
The combination of telmisartan and amlodipine in tablet form indicated for patients whose arterial blood pressure cannot be fully managed with monotreatment. The purpose of this study was to investigate the effect of the fixed combination telmisartan/amlodipine 80/5mg per day on arterial pressure levels and the variation of HOMA-IR, HOMA-B and QUICKI values in patients with stage 2 hypertension (systolic blood pressure (SBP) 160-179 mmHg and/or diastolic blood pressure (DBP) 100-109 mmHg) and with prediabetes (IFG/IGT) before and after the 3-month treatment with the administration of the fixed combination.
Methods
Data collected from 51 patients who have visited our outpatient clinic for lipid metabolism disorders during the period 2014-2018. 51 persons with BMI: 29.32 [27.37-31.65] (25 male, 16 female) had been randomized in the group for telmisartan/amlodipine 80/5mg per day.
The median values for the study’s sample in SBP and DBP were: 163[158-168] and 100[95-106] mmHg, respectively. Their somatometric and demographic characteristics were recorded in the beginning of the study and are presented on Table 1Α.
Results
The results of the variations in SBP and DBP, as well as the variations in glucose, insulin, HOMA-IR, HOMA-B and QUICKI before and after the 3-month treatment are presented on Table 1B.
Conclusions
From the sampled patients it can be observed that the 3-month treatment with telmisartan/amlodipine statistically significantly improved (p=0.005) the HOMA-IR values while improving fasting glucose and insulin levels. Finally, there was a statistically significant reduction in QUICKI values and a statistically insignificant reduction in HOMA-B.
Collapse
Affiliation(s)
- A Liontos
- University hospital of Ioannina, Ioannina, Greece
| | - A Papathanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - D Biros
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | | | - S Tsourlos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - L Athanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - C Veliani
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - NG Kolios
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - C Pappa
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Zarachi
- University Hospital of Ioannina, ENT departement, Ioannina, Greece
| | - E Christaki
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Liberopoulos
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - M Elisaf
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - H Milionis
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - G Liamis
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| |
Collapse
|
12
|
Liontos A, Papathanasiou A, Biros D, Papagiannopoulos C, Athanasiou L, Tsourlos S, Veliani C, Kolios NG, Pappa C, Zarachi A, Christaki E, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with valsartan/amlodipine in prediabetic hypertensive patients. Eur J Prev Cardiol 2022. [DOI: 10.1093/eurjpc/zwac056.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction-Purpose
The combination of valsartan with amlodipine is more effective than monotherapy for managing HT. The purpose of this study was to investigate the effect of the fixed combination of valsartan/amlodipine 160/5 mg per day on HOMA-IR (homeostatic model assessment for insulin resistance), HOMA-B (HOMA for β cell function) and QUICKI (quantitative insulin-sensitivity check index) values in patients with stage 2 hypertension (systolic arterial pressure 160-179 mmHg and/or diastolic pressure 100-109 mmHg) and prediabetes (IFG/IGT) before and after 3 months of treatment with the dual therapy.
Methods
Data from 54 patients who visited our outpatient clinic for lipid metabolism during the period 2014-2018. 54 persons were randomized in the valsartan/amlodipine group 160/5 mg per day (33 males/21 females from whom 14 were smokers and 8 were alcohol consumers) with BMI: 28.09[26.81-29.89], all of whom successfully completed the study. The median values of systolic and diastolic arterial pressure for the study population: 162 [159.25-165] and 100 [92-103.75] mmHg, respectively.
Results
The resulting variations of systolic and diastolic arterial pressure as well as the variations of HOMA-IR, HOMA-B and QUICKI are presented on Table 1.
Conclusions
From the studied group it is concluded that the 3-month treatment with valsartan/amlodipine improved with statistical significance the values of both systolic and diastolic arterial pressure (reduction by -13.58% and -13% for systolic and diastolic arterial pressure, respectively, p<0.001, for both values). Regarding glucose levels, there has also been a reduction by -0.04%, without statistical significance, while the increase of insulin levels (+16.13%) by the end of the 3-month period was also deemed statistically insignificant. Additionally, there have been noted statistically insignificant increases in HOMA-IR (+12.65%) and HOMA-B (+17%). Finally, no change has been observed in QUICKI values.
Collapse
Affiliation(s)
- A Liontos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Papathanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - D Biros
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | | | - L Athanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - S Tsourlos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - C Veliani
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - NG Kolios
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - C Pappa
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Zarachi
- University Hospital of Ioannina, ENT departement, Ioannina, Greece
| | - E Christaki
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Liberopoulos
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - M Elisaf
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - H Milionis
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - G Liamis
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| |
Collapse
|
13
|
Liontos A, Papathanasiou A, Biros D, Papagiannopoulos C, Tsourlos S, Athanasiou L, Zarachi A, Pargana E, Nasiou M, Veliani C, Christaki E, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with valsartan/amlodipine in prediabetic patients. Eur J Prev Cardiol 2022. [DOI: 10.1093/eurjpc/zwac056.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction-Purpose
The combination of valsartan with amlodipine is a commonly administered combination of an agonist ATII (angiotensin receptor II) and CCB (calcium channel blocker) for the management of hypertension. There is already data from different studies that describe the effect of each of those medications in the lipidemic profile. Ratios TRG/ApoA-1, TRG/HDLC are useful markers of insulin resistance. The purpose of this study is to investigate the effect of the fixed combination of valsartan/amlodipine 160/5mg per day on the levels of serum lipids, as well as the levels of serum apolipoproteins and the TRG/ApoA-1, TRG/HDLC ratios, in patients with stage 2 hypertension (systolic blood pressure (SBP) 160-179 mmHg and/or diastolic blood pressure (DBP) 100-109 mmHg) and prediabetes (IFG/IGT), before and after the 3-month treatment.
Methods
Data from 54 patients who were referred to our outpatient clinic for lipid metabolism disorders during the period 2014-2018 and had been randomized in the valsartan/amlodipine group 160/5mg per day. Those patients (33 male/21 female from whom 14 were smokers and 8 alcohol users) all completed the study successfully with mean BMI: 28.09[26.81-29.89]. The median values of SBP and DBP for the sample group were: 162 [159.25-165] και 100 [92-103.75] mmHg, respectively. The levels of apolipoproteins B, A-1, Lp(a) and E were measured prior to the beginning of treatment and 3-months after its administration.
Results
The resulting alternations of SBP and DBP levels before and after the 3-month treatment, as well as the changes of serum lipid, apolipoprotein levels and TRG/ApoA-1, TRG/HDL-C ratios are presented in Table 1.
Conclusions
From the sample group it seems like that the 3-month therapy with valsartan/amlodipine improved statistically significant both SBP and DBP levels (decreased by -13.58% and -13% respectively, p<0.001 for both values). Concerning lipid levels, no significant variation was observed across the board. Finally, no significant change was observed in apolipoprotein levels and TRG/ApoA-1, TRG/HDL-C ratios.
Collapse
Affiliation(s)
- A Liontos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Papathanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - D Biros
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | | | - S Tsourlos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - L Athanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Zarachi
- University Hospital of Ioannina, ENT departement, Ioannina, Greece
| | - E Pargana
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - M Nasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - C Veliani
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Christaki
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Liberopoulos
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - M Elisaf
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - H Milionis
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - G Liamis
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| |
Collapse
|
14
|
Yin W, Liontos A, Koepke J, Ghoul M, Mazzocchi L, Liu X, Lu C, Wu H, Fysikopoulos A, Sountoulidis A, Seeger W, Ruppert C, Günther A, Stainier DYR, Samakovlis C. An essential function for autocrine hedgehog signaling in epithelial proliferation and differentiation in the trachea. Development 2022; 149:274222. [PMID: 35112129 PMCID: PMC8918789 DOI: 10.1242/dev.199804] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Accepted: 12/07/2021] [Indexed: 12/12/2022]
Abstract
The tracheal epithelium is a primary target for pulmonary diseases as it provides a conduit for air flow between the environment and the lung lobes. The cellular and molecular mechanisms underlying airway epithelial cell proliferation and differentiation remain poorly understood. Hedgehog (HH) signaling orchestrates communication between epithelial and mesenchymal cells in the lung, where it modulates stromal cell proliferation, differentiation and signaling back to the epithelium. Here, we reveal a previously unreported autocrine function of HH signaling in airway epithelial cells. Epithelial cell depletion of the ligand sonic hedgehog (SHH) or its effector smoothened (SMO) causes defects in both epithelial cell proliferation and differentiation. In cultured primary human airway epithelial cells, HH signaling inhibition also hampers cell proliferation and differentiation. Epithelial HH function is mediated, at least in part, through transcriptional activation, as HH signaling inhibition leads to downregulation of cell type-specific transcription factor genes in both the mouse trachea and human airway epithelial cells. These results provide new insights into the role of HH signaling in epithelial cell proliferation and differentiation during airway development. Summary: A conserved autocrine role for HH signaling in tracheal epithelial cell proliferation and differentiation is revealed, suggesting potential new interventions for airway epithelial proliferation and differentiation defects.
Collapse
Affiliation(s)
- Wenguang Yin
- Cardio-Pulmonary Institute, Member of the German Center for Lung Research (DZL), University of Giessen and Marburg Lung Center (UGMLC), Justus Liebig University of Giessen, Giessen 35392, Germany.,State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510182, People's Republic of China.,Department of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Bad Nauheim 61231, Germany
| | - Andreas Liontos
- Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, S-10691 Stockholm, Sweden.,Science for Life Laboratory, Stockholm University, Solna 171 21, Sweden
| | - Janine Koepke
- Cardio-Pulmonary Institute, Member of the German Center for Lung Research (DZL), University of Giessen and Marburg Lung Center (UGMLC), Justus Liebig University of Giessen, Giessen 35392, Germany
| | - Maroua Ghoul
- Cardio-Pulmonary Institute, Member of the German Center for Lung Research (DZL), University of Giessen and Marburg Lung Center (UGMLC), Justus Liebig University of Giessen, Giessen 35392, Germany
| | - Luciana Mazzocchi
- Cardio-Pulmonary Institute, Member of the German Center for Lung Research (DZL), University of Giessen and Marburg Lung Center (UGMLC), Justus Liebig University of Giessen, Giessen 35392, Germany
| | - Xinyuan Liu
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510182, People's Republic of China
| | - Chunyan Lu
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510182, People's Republic of China
| | - Haoyu Wu
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510182, People's Republic of China
| | - Athanasios Fysikopoulos
- Cardio-Pulmonary Institute, Member of the German Center for Lung Research (DZL), University of Giessen and Marburg Lung Center (UGMLC), Justus Liebig University of Giessen, Giessen 35392, Germany
| | - Alexandros Sountoulidis
- Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, S-10691 Stockholm, Sweden.,Science for Life Laboratory, Stockholm University, Solna 171 21, Sweden
| | - Werner Seeger
- Cardio-Pulmonary Institute, Member of the German Center for Lung Research (DZL), University of Giessen and Marburg Lung Center (UGMLC), Justus Liebig University of Giessen, Giessen 35392, Germany.,Department of Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Bad Nauheim 61231, Germany
| | - Clemens Ruppert
- Cardio-Pulmonary Institute, Member of the German Center for Lung Research (DZL), University of Giessen and Marburg Lung Center (UGMLC), Justus Liebig University of Giessen, Giessen 35392, Germany
| | - Andreas Günther
- Cardio-Pulmonary Institute, Member of the German Center for Lung Research (DZL), University of Giessen and Marburg Lung Center (UGMLC), Justus Liebig University of Giessen, Giessen 35392, Germany
| | - Didier Y R Stainier
- Department of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Bad Nauheim 61231, Germany
| | - Christos Samakovlis
- Cardio-Pulmonary Institute, Member of the German Center for Lung Research (DZL), University of Giessen and Marburg Lung Center (UGMLC), Justus Liebig University of Giessen, Giessen 35392, Germany.,Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, S-10691 Stockholm, Sweden.,Science for Life Laboratory, Stockholm University, Solna 171 21, Sweden.,Department of Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Bad Nauheim 61231, Germany
| |
Collapse
|
15
|
Barkas F, Elisaf M, Liberopoulos E, Klouras E, Kei A, Liontos A, Megapanou E, Lamouri C, Rizos E. Non-alcoholic fatty liver disease and its association with incident diabetes in statin-treated individuals. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
16
|
Liamis G, Filippatos TD, Liontos A, Elisaf MS. MANAGEMENT OF ENDOCRINE DISEASE: Hypothyroidism-associated hyponatremia: mechanisms, implications and treatment. Eur J Endocrinol 2017; 176:R15-R20. [PMID: 27484454 DOI: 10.1530/eje-16-0493] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/08/2016] [Revised: 07/06/2016] [Accepted: 08/01/2016] [Indexed: 12/11/2022]
Abstract
BACKGROUND Patients with moderate to severe hypothyroidism and mainly patients with myxedema may exhibit reduced sodium levels (<135 mmol/L). SUMMARY The aim of this short review is the presentation of the mechanisms of hyponatremia and of the available data regarding its implications and treatment in patients with hypothyroidism. Hypothyroidism is one of the causes of hyponatremia, thus thyroid-stimulating hormone determination is mandatory during the evaluation of patients with reduced serum sodium levels. The main mechanism for the development of hyponatremia in patients with chronic hypothyroidism is the decreased capacity of free water excretion due to elevated antidiuretic hormone levels, which are mainly attributed to the hypothyroidism-induced decrease in cardiac output. However, recent data suggest that the hypothyroidism-induced hyponatremia is rather rare and probably occurs only in severe hypothyroidism and myxedema. Other possible causes and superimposed factors of hyponatremia (e.g. drugs, infections, adrenal insufficiency) should be considered in patients with mild/moderate hypothyroidism. Treatment of hypothyroidism and fluid restriction are usually adequate for the management of mild hyponatremia in patients with hypothyroidism. Patients with possible hyponatremic encephalopathy should be urgently treated according to current guidelines. CONCLUSIONS Severe hypothyroidism may be the cause of hyponatremia. All hypothyroid patients with low serum sodium levels should be evaluated for other causes and superimposed factors of hyponatremia and treated accordingly.
Collapse
Affiliation(s)
- G Liamis
- Department of Internal MedicineSchool of Medicine, University of Ioannina, Ioannina, Greece
| | - T D Filippatos
- Department of Internal MedicineSchool of Medicine, University of Ioannina, Ioannina, Greece
| | - A Liontos
- Department of Internal MedicineSchool of Medicine, University of Ioannina, Ioannina, Greece
| | - M S Elisaf
- Department of Internal MedicineSchool of Medicine, University of Ioannina, Ioannina, Greece
| |
Collapse
|
17
|
Christogiannis L, Kostapanos M, Kostara C, Barkas F, Liontos A, Panagiotopoulou T, Bairaktari E, Elisaf M. Effects of combinations of valsartan with amlodipine or hydrochlorothiazide on renal function and proteinuria in hypertensive patients with metabolic syndrome. Atherosclerosis 2014. [DOI: 10.1016/j.atherosclerosis.2014.05.790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|